AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9467047
Drug: Ondansetron (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (32 mg) administered as a 15-minute intravenous infusion
Trial: 8582214
Drug: Local arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local arterial infusion of 5-FU
Trial: 9760009
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg)
Trial: 4076202
Drug: Nicardipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (10 mg)
Trial: 27136906
Drug: Losmapimod 20
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod 20 mg
Trial: 22610801
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal misoprostol (1000 micrograms)
Trial: 28292361
Drug: Intramuscular oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular oxytocin (10 units)
Trial: 19702597
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg/day (n=9)
Trial: 16153354
Drug: CMHN problem-solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMHN problem-solving treatment
Trial: 7930304
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids
Trial: 1100179
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate treatment after craniospinal irradiation
Trial: 24091311
Drug: HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 vaccine (Cervarix®; GlaxoSmithKline Vaccines)
Trial: 15188794
Drug: Maintenance oral
RxNorm normalized name: Cystex Urinary Health Maintenance oral soluti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance oral nifedipine therapy (n=37) administered 20 mg every six hours
Trial: 15188794
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (controls, n=36)
Trial: 15188794
Drug: Maintenance oral
RxNorm normalized name: Cystex Urinary Health Maintenance oral soluti
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance oral nifedipine therapy (n=37)
Trial: 27939836
Drug: Triptorelin 22.5
RxNorm normalized name: triptorelin 22.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 22.5 mg given as 24-week depot injections
Trial: 31935529
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT), maximum 26 sessions, up to six months
Trial: 30121618
Drug: Multisession cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisession cognitive-behavioural therapy (CBT)
Trial: 30121618
Drug: One-session treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session treatment (OST)
Trial: 19887866
Drug: Capecitabine monotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine monotherapy (64% of patients, median starting dose 1,070 mg/m² b.i.d.)
Trial: 14766712
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at a starting rate of 6-9 microg kg(‐1) h(‐1) for up to 72 h, with additional propofol (0.5 mg kg(‐1) h(‐1) if required)
Trial: 8183520
Drug: Systemic flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic flurbiprofen (added to topical drugs)
Trial: 28200002
Drug: AbobotulinumtoxinA solution
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA solution for injection (ASI) 50 U
Trial: 27765756
Drug: Nivolumab 10
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 10 mg/kg + gemcitabine/cisplatin (arm A)
Trial: 25903058
Drug: Prompt group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt group (INT) received three daily screen-based prompts for 12 weeks.
Trial: 12534402
Drug: onercept 11.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onercept 11.7 mg three times weekly for 2 weeks
Trial: 12534402
Drug: onercept 50
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onercept 50 mg three times weekly for 2 weeks
Trial: 9275422
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg twice with 12 hours apart (Group 1)
Trial: 9275422
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of mifepristone 25 mg (Group 2)
Trial: 9275422
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg and anordrin 7.5 mg given once (Group 3)
Trial: 17995496
Drug: E2/NETA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NETA (1 mg 17beta estradiol plus 0.5 mg norethisterone acetate daily for 48 weeks)
Trial: 17995496
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg daily for 48 weeks)
Trial: 11498060
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (low ejection fraction subgroup)
Trial: 3063047
Drug: Alinidine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine (0.6 mg.kg‐1 i.v.)
Trial: 3063047
Drug: Metoprolol (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.035 mg.kg‐1 i.v.)
Trial: 19393840
Drug: Extended-release quetiapine
RxNorm normalized name: quetiapine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release quetiapine fumarate (XR)
Trial: 19393840
Drug: Immediate-release quetiapine
RxNorm normalized name: quetiapine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release quetiapine fumarate (IR)
Trial: 7883933
Drug: Intramuscular sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular sedation (meperidine and promethazine)
Trial: 2204333
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of papaveretum (n = 8)
Trial: 28381198
Drug: Clopidogrel combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel combined with aspirin
Trial: 12787540
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin and aspirin
Trial: 9403227
Drug: Tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone 200 mg
Trial: 25050456
Drug: Ciprofloxacin DPI
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin DPI 65 mg
Trial: 17560446
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (12-h intervals)
Trial: 17560446
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (3-h intervals)
Trial: 11426001
Drug: 2 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mmol/L gadoteridol
Trial: 11426001
Drug: 4 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mmol/L gadoteridol
Trial: 8008413
Drug: Phentolamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (30 mg) administered intravenously
Trial: 1987713
Drug: Nifedipine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (80 mg/day, 4 times per day)
Trial: 25486290
Drug: Nifedipine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (80 mg/day)
Trial: 27884418
Drug: 700 cGy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 cGy dose of radiation
Trial: 26919705
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with chin bone
Trial: 26919705
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with chin bone plus a membrane
Trial: 10575270
Drug: BCG immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG immunotherapy (standard regimen)
Trial: 30033196
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping (KT) applied every 3 days for children with up to three incontinence episodes per day, and daily for those with more frequent episodes
Trial: 22803423
Drug: PPI +
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI + DG group (Rabeprazole 20 mg once daily; DG 6 g thrice daily)
Trial: 22803423
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group A (Rabeprazole Capsule 20 mg once daily)
Trial: 22803423
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group B (Rabeprazole 20 mg once daily; Domperidone 10 mg thrice daily)
Trial: 9204744
Drug: Conventional cholecystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cholecystectomy (CC)
Trial: 31600487
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy alone
Trial: 31600487
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy in combination with an immunomodulator
Trial: 25990414
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined oral contraceptive (ethinylestradiol 20 μg/desogestrel 150 μg)
Trial: 17907591
Drug: HFA-based budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HFA-based budesonide inhaler therapy
Trial: 17907591
Drug: High-dosage (1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage (1,600 microg/day) HFA and CFC inhalers
Trial: 9146848
Drug: Triazolam +
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triazolam + Diltiazem (0.25 mg triazolam after 3-day treatment of 180 mg diltiazem)
Trial: 2885203
Drug: Diphenhydramine 50
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 50 mg with alcohol 32 ml
Trial: 2885203
Drug: Acrivastine 8
RxNorm normalized name: acrivastine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acrivastine 8 mg with alcohol 32 ml
Trial: 2885203
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg and 120 mg with alcohol 32 ml
Trial: 16893273
Drug: Contingency Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency Management with Cognitive-Behavioral Therapy (CM+CBT)
Trial: 16893273
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy alone (CBT)
Trial: 20471542
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication order
Trial: 20471542
Drug: Review of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Review of pain treatment plan
Trial: 20471542
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in pain medication
Trial: 20471542
Drug: Monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring of analgesic-induced side effects
Trial: 20471542
Drug: Documentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Documentation of nonpharmacological therapies
Trial: 12752032
Drug: Hallucination focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hallucination focused Integrative Treatment (HIT)
Trial: 8604439
Drug: Predicted drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predicted drug efficacy
Trial: 6218104
Drug: Mezlocillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (2 g intravenously before surgery and every eight hours until the fifth postoperative day)
Trial: 17413103
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g fat/d (2.4 g fat/meal)
Trial: 31044688
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to treatment
Trial: 11172269
Drug: Pneumatic compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pneumatic compression therapy delivered after elective hip surgery
Trial: 7842828
Drug: Teicoplanin plus
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin plus pefloxacine 10 mg/kg
Trial: 22942727
Drug: ASA monotherapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA monotherapy
Trial: 31227453
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LIPUS treatment)
Trial: 28304224
Drug: Evolocumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (140 mg every 2 weeks or 420 mg monthly)
Trial: 23880306
Drug: ART according
RxNorm normalized name: clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART according to national treatment eligibility guidelines (CD4 <350 cells/μL, WHO stage 3 or 4 disease, or multidrug/extensively drug-resistant tuberculosis)
Trial: 21714857
Drug: Fenoldopam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (1 μg/kg/min continuous infusion during CPB)
Trial: 9135945
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.05 IU/kg)
Trial: 9135945
Drug: Insulin (correctly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (correctly informed)
Trial: 9135945
Drug: Insulin (expectation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (expectation without knowledge)
Trial: 3777587
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal (OAC) given in four doses at three-hour intervals starting three hours after SRT dosing (Group 3)
Trial: 26689566
Drug: Alisertib (MLN8237)
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib (MLN8237) 50 mg enteric-coated tablet under fed conditions
Trial: 26689566
Drug: Alisertib (MLN8237)
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib (MLN8237) 50 mg enteric-coated tablet under fasted conditions
Trial: 26689566
Drug: Alisertib (MLN8237)
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib (MLN8237) 50 mg enteric-coated tablet
Trial: 10545552
Drug: iNO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNO at 20 ppm (after initial treatment with 0 ppm)
Trial: 10545552
Drug: Low-dose iNO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iNO group (2 ppm)
Trial: 22196566
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no massage therapy)
Trial: 3724994
Drug: Electrical shocks
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical shocks administered to the right forearm at four intensities
Trial: 21192262
Drug: Immunotherapy (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (specific agents not detailed)
Trial: 21192262
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (specific agents not detailed)
Trial: 12799847
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg and 100 mg
Trial: 9085303
Drug: Tramadol (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (higher doses)
Trial: 3113538
Drug: Antibiotics given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics given to patients with proved bacteriuria (80 patients)
Trial: 3113538
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (8 untreated patients with bacteriuria)
Trial: 24643905
Drug: Odanacatib 50
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib 50 mg weekly for 2 years
Trial: 19941679
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g butter with no Mg supplementation (fat-only meal)
Trial: 15823831
Drug: tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibolone 2.5 mg
Trial: 17085380
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol and 2 mg dienogest (E2/dienogest)
Trial: 12660934
Drug: Control vector
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control vector (rabies virus glycoprotein G gene)
Trial: 10823400
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (75 mg)
Trial: 10823400
Drug: Tea (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea (75 mg caffeine)
Trial: 6353831
Drug: FK 33-824
RxNorm normalized name: FK-960
DrugBank: FK-960 (DB06465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK 33-824 (0.5 mg im injection)
Trial: 28420909
Drug: Intrauterine lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine lidocaine infusion
Trial: 28420909
Drug: Control (4ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (4ml intravenous normal saline)
Trial: 23882146
Drug: 1,3-dimethylamylamine supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,3-dimethylamylamine supplement
Trial: 17046034
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (5 g of creatine monohydrate, four times a day for 7 days)
Trial: 76224
Drug: Five-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug regimen
Trial: 31586999
Drug: Topical adapalene
RxNorm normalized name: adapalene Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with explicative leaflet (G1)
Trial: 31586999
Drug: Topical adapalene
RxNorm normalized name: adapalene Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with SMS reminders (G2)
Trial: 31586999
Drug: Topical adapalene
RxNorm normalized name: adapalene Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with standard instructions (G3)
Trial: 25041252
Drug: Platform-switching implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switching implants placed 1 mm below bone level (test group)
Trial: 25041252
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed at bone level (control group)
Trial: 1388115
Drug: Nifedipine R
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine R (20-40 mg b.i.d.)
Trial: 3890436
Drug: Metronidazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1 g)
Trial: 3890436
Drug: Doxycycline (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (0.2 g)
Trial: 24682319
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg/week)
Trial: 18073060
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy (100 mg/d)
Trial: 18073060
Drug: Lamivudine combined
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine combined with individualized low-dose HBIG